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Abstract 
Objective: Precision medicine drug therapy seeks to maximise efficacy and 
minimise harm for individual patients. This will be difficult if drug response and side-
effects are positively associated, meaning patients likely to respond best are at 
increased risk of side-effects. We applied joint longitudinal-survival models to 
evaluate associations between drug response (longitudinal outcome) and risk of 
side-effects (survival outcome) for patients initiating type 2 diabetes therapy. 
Study Design and Setting: Participants were randomised to metformin, 
sulfonylurea or thiazolidinedione therapy in the ADOPT drug-efficacy trial (n=4,351). 
Joint models were parameterised for: 1) current HbA1c response (change from 
baseline in HbA1c); 2) cumulative HbA1c response (total HbA1c change).  
Results: With metformin, greater HbA1c response did not increase risk of 
gastrointestinal events (Hazard ratio (HR) per 1% absolute greater current response 
0.82 (95% confidence interval 0.67,1.01); HR per 1% higher cumulative response 
0.90 (0.81,1.00)). With sulfonylureas, greater current response was associated with 
increased risk of hypoglycaemia (HR 1.41 (1.04,1.91)). With thiazolidinediones, 
greater response was associated with increased risk of oedema (current HR 1.45 
(1.05,2.01); cumulative 1.22 (1.07,1.38)) but not fracture.  
Conclusion: Joint modelling provides a useful framework to evaluate the 
association between response to a drug and risk of developing side-effects. There 
may be great potential for widespread application of joint modelling to evaluate the 
risks and benefits of both new and established medications. 
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Plain Language Summary 
Purpose of study 
 An overlooked question in precision / stratified medicine and when evaluating 
new medications is: are the benefits and risks of a drug associated?  
 
 Joint longitudinal-survival models can be applied when, as in type 2 diabetes, 
drug response is measured by a longitudinal biomarker (HbA1c) and risks of 
side-effects can be represented as a time-to-event outcome. 
What did we do and find? 
 We used joint longitudinal-survival models to show novel associations 
between the benefit of greater drug response and the risk of common side-
effects for 3 glucose-lowering medications for patients with type 2 diabetes.  
 
 Greater drug response was associated with increased risk of hypoglycaemia 
with sulfonylureas and oedema with thiazolidinediones. In contrast there was 
no evidence of an increased risk of gastro-intestinal side-effects with 
metformin. 
What do the findings mean? 
 Joint models provide a novel, flexible and robust approach to study the 
associations between the risks and benefits of drug therapy.  
 Precision / stratified medicine studies seeking to identify patients or 
subgroups likely to respond well to a drug should also evaluate whether the 
same patients are at increased risk of side-effects.  
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Introduction 
There is increasing interest in applying a precision medicine approach to select the 
most appropriate drug for a patient or subgroup of patients, in order to either improve 
response or to reduce side-effects.1 2 An important but overlooked question, 
particularly if side-effects are a result of the primary pharmacological effect of the 
drug, is whether the patients most likely to benefit are also at greatest risk of side-
effects. Type 2 diabetes is an ideal candidate for precision medicine as there are 
many drug options to lower blood glucose (as measured by HbA1c), but each drug 
has a different mechanism of action and specific side-effects. However, the 
association between HbA1c response and side-effects is unknown for all drug 
options. If patients likely to have a greater HbA1c response to a specific drug are 
also at increased risk of side-effects this may limit the clinical utility of any precision 
approach to type 2 diabetes therapy. 
To date, no robust framework has been proposed to evaluate the association 
between drug response and risk of side-effects. In type 2 diabetes, HbA1c is 
measured repeatedly over time (a longitudinal process), whilst side-effect risk can be 
modelled as a time-to-event process. In this scenario, joint longitudinal-survival 
modelling is the preferred approach to evaluate the association between both 
processes.3-6 Joint models attempt to capture the true, unobserved, longitudinal 
trajectory (in reality HbA1c is measured intermittently and is subject to measurement 
error from random noise and biological variation). This means joint models can 
reduce bias and improve efficiency compared with simpler approaches.5 7 Joint 
models have been applied in many diseases including recently in type 1 diabetes 
(autoantibodies and time to disease onset),8-11 but not to our knowledge in type 2 
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diabetes, or more broadly to evaluate the association between drug response and 
risk of side-effects. 
In this study we applied joint modelling to evaluate the association between drug 
response and risk of established side-effects for 3 widely used type 2 diabetes 
drugs, and thus further evaluate the potential for precision drug therapy in type 2 
diabetes.  
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Material and Methods 
Overview 
Our aim was to understand whether the degree of glycaemic response to three 
common glucose-lowering drugs altered the risk of developing a side-effect. To 
answer this question we examined the association between two outcomes: 1) HbA1c 
response (as measured by change from baseline in HbA1c) and 2) risk of developing 
a side-effect (gastro-intestinal (GI) events, hypoglycaemia, oedema and fracture).  
Setting and design 
We used individual participant level data from the ADOPT randomised trial,12 
accessed through Clinical Trial Data Transparency Portal under approval from GSK 
(Proposal-930).13 ADOPT was a prospective head-to-head drug trial including 
treatment-naïve participants with type 2 diabetes who were randomised to Metformin 
(MFN), the sulfonylurea (SU) glyburide or the thiazolidinedione (TZD) rosiglitazone 
(n=4,351 participants). The aim of ADOPT was to evaluate the long-term efficacy of 
the TZD compared to SU and MFN and the primary outcome was time to therapy 
failure (confirmed fasting plasma glucose ≥180 mg/dl). Study visits were every 2 
months in year 1, then every 3 months up to 5 years. Clinically determined adverse 
events were recorded at each study visit, including records of GI events, 
hypoglycaemia, oedema and fracture. Biomarkers including HbA1c were recorded at 
each visit. ADOPT participants in the intention to treat population with a valid 
baseline HbA1c were eligible for our study. Participants were censored if they 
reached the trial primary endpoint of glycaemic failure, trial-recorded study 
withdrawal, or at 5 years after starting therapy as in the ADOPT main analysis.  
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Study outcomes  
Our time-to-event outcomes were the first occurrence of 4 established drug-specific 
side-effects, over a 5 year period. For MFN the outcome of interest was a GI event, 
for SU it was a hypoglycaemia event (patient self-reported) and for TZD we 
evaluated oedema events and bone fractures.12 Each drug and side-effect was 
analysed separately. We excluded patients with a pre-trial history of oedema from 
the oedema analysis (6% of patients), but pre-trial hypoglycaemia, gastro-intestinal 
and fracture records were not available to do the same for other side-effects. Due to 
the high number of GI events we repeated the GI analysis restricted to only 
moderate/severe and severe events as sensitivity analysis. The longitudinal outcome 
of interest was HbA1c response as measured by change from baseline in HbA1c 
(HbA1c at each study visit (%) – baseline HbA1c (%)). Throughout HbA1c 
percentages refer to absolute values rather than percentage changes. To test the 
specificity of our findings we repeated the analysis for each side-effect for the other 
drugs. 
Statistical analysis 
We used a joint model with two parameterisations (Models 1-2) and two standard 
time-to-event models (Models 3-4), for comparison, to evaluate the association 
between HbA1c response and the risk of developing a side-effect. A fundamental 
difference between each model was in the method to estimate HbA1c response, as 
illustrated in Figure 1. Each side-effect was evaluated separately and the same 
modelling approach was applied for each side-effect. Participants were followed-up 
for up to five years from randomisation. As we were assessing the association 
between side-effects and response, all participants required at least one pre-side-
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effect HbA1c measure (meaning 4% of participants with very early side-effects were 
excluded from oedema analysis, 3% fracture, 20% hypoglycaemia, 12% GI). All 
models were adjusted for baseline HbA1c.14 Model setups were as follows: 
Joint longitudinal-survival models 
We used a maximum likelihood joint longitudinal-survival model to simultaneously 
assess the association between HbA1c response (longitudinal process) and the risk 
of developing a side-effect (survival process). The joint model consisted of a two 
parts: a longitudinal submodel and a survival submodel linked through shared 
subject-specific random effects.6  
In the general survival submodel, the hazard for patient 𝑖 (ℎ𝑖(𝑡)) can be represented 
as:  
ℎ𝑖(𝑡) = ℎ0(𝑡) exp(𝑤𝑖
𝑇𝛾 + 𝛼𝑚𝑖(𝑡)), 
where ℎ0(𝑡) is the baseline hazard, 𝑤𝑖 are baseline covariates, 𝛾 are regression 
coefficients, 𝑚𝑖(𝑡) is the “true, unobserved” longitudinal biomarker (estimated from 
the longitudinal submodel) and 𝛼 quantifies the association between the longitudinal 
biomarker and the time-to-event process.6  
We derived 𝑚𝑖(𝑡) from the observed HbA1c response data using a linear mixed 
effects model with a non-linear term for time (as HbA1c response is typically non-
linear): 
𝑦𝑖(𝑡) =  𝑚𝑖(𝑡) +  𝜖𝑖(𝑡) 
         = 𝛽0 + 𝛽1𝑁(𝑡𝑖)1 + 𝛽2𝑁(𝑡𝑖)2  +  𝛽3Baseline HbA1c +  𝑏𝑖0 +  𝑏𝑖1𝑁(𝑡𝑖)1 +  𝑏𝑖2𝑁(𝑡𝑖)2 +
 𝜖𝑖(𝑡), 
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where 𝑦𝑖 is the observed HbA1c change from baseline and 𝑚𝑖 the “true”, unobserved 
HbA1c change from baseline. 𝑁(𝑡𝑖)1 𝑎𝑛𝑑 𝑁(𝑡𝑖)2 denote the basis for a non-linear 
natural cubic spline of time with 1 internal knot at the 50th percentile of follow-up 
time (included in both the fixed and random effect parts of the longitudinal HbA1c 
submodel), 𝑏𝑖 is a vector of subject specific random effects, 𝑏𝑖 ~ 𝛮(O, D̃) where D̃ is 
the unstructured covariance matrix of random effects, 𝜖𝑖 is the vector of residuals, 
and 𝜖𝑖 ~ 𝛮(O, 𝜎
2) where 𝜎2 𝑖s the covariance matrix of the residuals.6 For models of 
hypoglycaemia with metformin and oedema with sulfonylureas we used a linear term 
for the random effect of time to achieve model convergence. 
Model 1: Joint model current value (JMcv). To assess the association between the 
current value of HbA1c response and risk of side-effects (the standard formulation of 
the joint model) we incorporated 𝑚𝑖 from the longitudinal submodel as a time-
dependent covariate in the survival submodel: 
ℎ𝑖(𝑡) = ℎ0(𝑡) exp{𝛾0Baseline HbA1c + 𝛼𝑚𝑖(𝑡)} 
Model 2: Joint model cumulative HbA1c (JMcum). To evaluate whether the risk of 
side-effects was associated with total rather than current HbA1c response we 
specified a second formulation of the joint model to assess the association between 
cumulative HbA1c response (total HbA1c response estimated as area-under-the-
curve) and risk of side-effects, by including ∫ 𝑚𝑖(𝑠) 𝑑𝑠}
𝑡
0
, the integral of the 
longitudinal HbA1c response trajectory up to time t, in the time-to-event submodel:6 
15 
ℎ𝑖(𝑡) = ℎ0(𝑡)exp {𝛾0Baseline HbA1c + 𝛼 ∫ 𝑚𝑖(𝑠) 𝑑𝑠}
𝑡
0
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For models 1 and 2 we used a B-spline with 5 internal knots to flexibly model the 
baseline hazard function. We examined the fit of submodels using residual plots. 
Models 1 and 2 were fitted using the JM package in R.16 
Model 3: Last-observation-carried-forward analysis (LOCF). We included observed 
HbA1c response (HbA1c at time t – baseline HbA1c) as a time-dependent covariate 
in a Cox proportional hazards model. This approach does not correct for 
measurement error and assumes HbA1c response is constant between 
measurements. Hazard ratios represent the increased risk of a side-effect for a 1-
unit (%) absolute increase in the most recent value of HbA1c change from baseline 
at time t. 
Model 4: single estimate of HbA1c response at 6 months (6mR). We evaluated the 
association between HbA1c response at six months and subsequent risk of 
developing a side-effect. In this two-stage approach we first estimated a single 
estimate of HbA1c response as a change score at 6 months. In the second stage we 
used this estimate as the exposure in a Cox hazards survival model with delayed 
entry to 6 months. Participants who developed a side-effect prior to 6 months or had 
no HbA1c record at 6 months were excluded from this analysis (Supplementary 
Table 4).  
Ethics approval 
Data for the ADOPT trial were accessed through the Clinical Trial Data 
Transparency Portal, with study approval from GlaxoSmithKline (Proposal 930).  
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Results 
The most common side-effects were GI side-effects with metformin (37%), followed 
by hypoglycaemia with sulfonylurea therapy (26%). Thiazolidinedione side-effects 
were less common (oedema 13%, fracture 7%, Table 1). Median follow-up was 
greater than 2.5 years in each cohort. For other participant characteristics see 
Supplementary table 1. Each side-effect occurred more frequently on these 
therapies than on the comparator drugs (Supplementary table 2).  
 
Joint-model associations between HbA1c response and risk of side-effects 
 
GI events. With metformin we found consistent evidence for an association between 
greater HbA1c response and reduced risk of a GI side-effect (Figure 2a). We 
observed a similar association for moderate/severe GI events (20% of patients) and 
no association for severe GI events (3% of patients) (Supplementary table 3). We 
found no evidence of an association with thiazolidinediones and sulfonylureas (Table 
2, Supplementary table 3).  
 
Hypoglycaemia. With sulfonylureas we found greater current HbA1c response was 
associated with an increased risk of hypoglycaemia (Model 1:JMcv, Figure 2b). We 
found no evidence for an association between the risk of hypoglycaemia and 
cumulative HbA1c response (Model 2:JMcum). With thiazolidinedione therapy, 
although the absolute risk of hypoglycaemia was much lower than with sulfonylurea 
therapy (8% versus 26%),  greater current and cumulative HbA1c response were 
associated with an increased risk of hypoglycaemia. There was no evidence of an 
association between response and hypoglycaemia with metformin (Table 2). 
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Oedema: With thiazolidinediones, greater current (Model 1:JMcv) and cumulative 
(Model 2:JMcum) HbA1c response were associated with an increased risk of 
oedema (Figure 2c). We found no evidence of an association between HbA1c 
response and risk of oedema with metformin and sulfonylureas (Table 2). 
 
Fracture: With thiazolidinediones we found no evidence for an association between 
HbA1c response and the risk of a fracture (Figure 2d). There was also no evidence 
of an association with metformin and sulfonylureas (Table 2, Supplementary table 6). 
 
Associations using standard time-to-event approaches 
Results using the last-observation-carried-forward approach (Model 3:LOCF) were 
generally consistent with those from the current value joint model (Model 1:JMcv) 
(Table 2, Figure 2). The exception was for thiazolidinediones and oedema, for which, 
in contrast to the joint model, we found no evidence of an association using the 
LOCF model. Using Model 4:6mR (where HbA1c response was estimated from a 
single 6 month value) we found no evidence of any association between HbA1c 
response and risk of side-effects except for gastrointestinal events with Metformin 
(hazard ratio per 1% absolute increase in 6 month HbA1c response 0.74 (95% CI 
0.60, 0.91, Supplementary Table 4-5). 
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Discussion  
Our study shows joint modelling can be a useful approach for evaluating 
associations between the benefits and risks of drug therapy. Using joint models for 
longitudinal and time-to-event data we were able to show important differences in the 
associations between drug response and risk of established side-effects for three 
widely-used type 2 diabetes drugs. We also found differences in the association 
between each of current and cumulative drug response and risk of side-effects, 
suggesting underlying differences in the nature of associations for the different 
drugs. Our results have implications for any precision medicine approach to type 2 
diabetes therapy. More generally, they highlight the potential for widespread 
application of joint longitudinal-survival modelling to evaluate the benefits and risks 
of both new and established medications. 
 
Advantages and disadvantages of joint models to evaluate the association 
between drug response and risk of side-effects 
 
We found a key advantage of joint modes to be their flexibility. Different 
specifications of the joint model gave important additional insight into the underlying 
nature of associations between HbA1c response and side-effects. These insights 
fitted with what is known about the pharmacological action of the different drugs. 
Current, but not cumulative, HbA1c response was associated with an increased risk 
of hypoglycaemia with sulfonylureas. This is expected as hypoglycaemia is a side-
effect related to short term fluctuations in blood glucose, rather than long term 
exposure. In contrast, for oedema with thiazolidinediones, which is less likely to 
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relate to short-term fluctuations in blood glucose, we observed associations for both 
current and cumulative HbA1c response. 
 
We also found associations with joint models that were missed by simpler 
approaches. With oedema with thiazolidinedione therapy there was no association 
using the last-observation-carried-forward approach but a clear association using 
both specifications of the joint model. This is likely due to the reduced bias and 
increased efficiency of the joint model compared with the last-observation-carried-
forward approach which does not correct for measurement error in the longitudinal 
HbA1c response.5 7 In general, hazard ratios using the last-observation-carried-
forward approach had the same direction of association but were attenuated 
compared with those obtained from the current value joint model, in keeping with 
previous comparisons.4 17 We found a single measure of HbA1c at 6 months was 
insufficient to show evidence of an association between HbA1c response and side-
effects, with the exception of GI side-effects with metformin where the association 
was consistent with the joint model.  
 
There are some settings where joint models may be more limited. ADOPT was a 
large randomised, double-blinded trial and in this dataset we found joint models to be 
useful to evaluate the association between response and relatively common side-
effects. Increasingly, similar trial datasets are available for researchers to address 
secondary research questions.13 18 It may be more challenging to apply joint 
modelling in other datasets. In particular, the potential of recording bias should be 
considered if conducting similar studies in electronic health records, although greater 
sample size may offer the opportunity to study rarer side-effects. Testing the 
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specificity of results to drugs known to cause the side-effect by comparison with 
‘negative control’ drugs may be a useful starting point. Joint models may also be 
harder to apply to study associations between drug response and acute or allergic 
side effects that occur immediately after starting therapy. This was apparent in our 
analysis, as although we included over 1000 participants for each drug, participants 
who developed an early side-effect prior to their on-therapy HbA1c were excluded, 
and this is a particular limitation of our analysis of hypoglycaemia with sulfonylureas. 
Another limitation of the joint modelling framework applied in this study is the 
assumption of a fixed association between longitudinal HbA1c and risk of each side 
effect. Whilst inspection of residual plots indicated this was an appropriate strategy, it 
is certainly plausible that associations could change with therapy duration, and 
incorporating duration of therapy as a time-varying effect within the joint modelling 
framework would be of considerable interest. Similarly, an extension of the joint 
modelling framework to robustly incorporate drug dose could yield further insight to 
complement the response:side-effect associations evaluated in this study. Evaluating 
the impact of dose is a particular challenge in trials of drug efficacy such as ADOPT, 
as participants could be both uptitrated based on reaching glycaemic thresholds and 
down-titrated if a randomised medication was poorly tolerated.  
 
Implications for a precision medicine approach to type 2 diabetes therapy 
 
Our findings for the different drugs have implications for any future precision 
medicine approach to type 2 diabetes therapy. Greater metformin drug response 
was not associated with an increased risk of gastro-intestinal side-effects and this 
suggests great potential to target therapy if patients likely to have greater drug 
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response can be robustly identified.19 However, targeting sulfonylureas and 
thiazolidinediones to patients may be difficult as good responders are likely to be at 
increased risk of, respectively, hypoglycaemia and oedema. Our findings highlight 
the vital importance of considering both differential drug response and risk of side-
effects in precision medicine studies, and this has been overlooked in previous 
work.20 21 
 
Our findings do not however preclude a precision medicine approach for 
sulfonylureas and thiazolidinediones. Identification of characteristics associated with 
either, but not both, improved drug response and lower risk of side-effects may allow 
the targeting of these therapies. Furthermore, decisions on therapy should ultimately 
be informed by absolute rather than relative risks of benefit or harm.1 For example, if 
patients likely to respond well to a thiazolidinedione can be identified then a 
thiazolidinedione may still be an appropriate option for patients whose absolute risk 
of developing a side-effect is sufficiently low. 
 
Comparison with other studies  
 
To our knowledge this is the evaluation of the association between HbA1c response 
and risk of side-effects for any of the three drugs, except for hypoglycaemia with 
sulfonylureas. Our results for sulfonylureas are consistent with previous 
observational studies that have examined the association between hypoglycaemia 
and achieved on-therapy HbA1c (rather than HbA1c response).22 23 In the ACCORD 
trial, participants with greatest HbA1c response at 4 months had a reduced rather 
than increased risk of hypoglycaemia, although this can be explained by the fact that 
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in ACCORD the participants with least initial response were more likely to be on 
Insulin, the therapy with by far the strongest association with hypoglycaemia.24   
 
In this study we found an unexpected association between greater response to TZD 
therapy and increased risk of hypoglycaemia, but no evidence of an association with 
metformin response, which would have indicated a positive association between 
increased drug response and increased risk of hypoglycaemia was a more general 
characteristic of glucose-lowering therapy. This is an interesting finding and one for 
which there is not a clear biological explanation, and it would be of interest to 
examine whether the TZD association can be replicated in other datasets. The 
association between oedema and HbA1c response with thiazolidinediones is not 
unexpected as the mechanisms underlying both glucose-lowering and fluid retention 
are both thought to relate to PPARy stimulation.25 With metformin there is no clear 
biological reason for the association between greater HbA1c response and a lower 
risk of gastro-intestinal events. One possible explanation is decreased drug 
adherence in patients experiencing mild gastro-intestinal symptoms prior to the event 
being recorded.  
Future work 
There is great potential to apply joint modelling to evaluate the association between 
drug response and risk of side-effects for the other drug options in type 2 diabetes 
and to study drug therapy in other diseases. Our findings also suggest a potential 
application of joint modelling as an efficient tool for understanding the risk-benefit 
trade-off at the individual-level in drug development.26 For precision medicine, the 
joint models used in this study could be extended to explore clinical features and 
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biomarkers associated with drug response, risk of side-effects, or both.27 28 
Alternative model specifications, such as evaluation of the effect of HbA1c response 
slope,6 the weighting of cumulative HbA1c effects by recency,15 the incorporation of 
multiple longitudinal biomarkers,29 or incorporation of time-varying drug effects, may 
provide further insight into the nature of associations between response and side-
effects. Similarly, incorporation of robust dose adjustment within the joint modelling 
framework, for example testing weighted cumulative drug associations,30 31 could 
allow much greater understanding of the impact of different levels of drug exposure 
on both response and adverse events. These are areas of current methodological 
development; a general mathematical presentation of joint modelling for 
simultaneously evaluating risks and benefits of medication would be a useful next 
step.  
 
Conclusions 
 
Joint modelling is a useful and efficient method to evaluate associations between 
continuous drug response and time to side-effects. Our study suggests the potential 
for application of joint modelling in both drug development and precision medicine 
research to evaluate the benefits and risks of medications. In type 2 diabetes, any 
future precision approach to sulfonylurea and thiazolidinedione therapy should 
consider the likely increased risk of respectively, hypoglycaemia and oedema, if 
targeting these therapies at patients likely to have the greatest drug response. 
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Table 1: Participant Numbers and Study Follow-up for each Primary Drug:Side-effect 
Cohort (Models 1-3). Data are median (IQR) unless stated. See Supplementary table 4 for 
participants included in Model 4).  
  Metformin - GI SU - Hypo TZD - Oedema TZD - Fracture 
No. of participants 1200 1052 1241 1311 
No. of events (%) 440 (37%) 270 (26%) 164 (13%) 88 (7%) 
Baseline HbA1c % 7.3 (6.7;7.9) 7.3 (6.7;7.9) 7.3 (6.7;7.9) 7.3 (6.7;7.9) 
No. recorded HbA1c 13 (6;19) 12 (5;19) 18 (9;20) 18 (10;21) 
Study follow-up (years) 2.8 (1.0;4.2) 2.5 (0.9;4.2) 4.0 (1.8;4.7) 4.0 (2.1;4.7) 
 
 
 
 
 
Table 2: Hazard ratios for the Association between HbA1c Response and Risk of Side-
effects (Models 1-3). Hazard ratios (95% Confidence Intervals) represent the increase in 
risk of a side-effect for a 1% greater absolute HbA1c response. A hazard ratio greater than 1 
indicates an increased risk of a side-effect with greater HbA1c response. 
 
Side-effect Model 1: JMcv Model 2: JMcum Model 3: LOCF 
 
MFN   
Gastrointestinal 0.82 (0.67, 1.01), P=0.06 0.90 (0.81, 1.00), P=0.06 0.85 (0.74, 0.96), P=0.01 
Hypoglycaemia 1.01 (0.63, 1.62), P=0.96 1.22 (0.93, 1.60), P=0.15 1.19 (0.88, 1.60), P=0.25 
Oedema 1.16 (0.70, 1.92), P=0.58 1.09 (0.88, 1.36), P=0.42 1.07 (0.74, 1.56), P=0.71 
Fracture 0.83 (0.48, 1.44), P=0.51 1.00 (0.78, 1.27), P=0.98 0.98 (0.69, 1.39), P=0.92 
 
SU 
Gastrointestinal 0.88 (0.69, 1.11), P=0.28 1.03 (0.92, 1.17), P=0.58 0.90 (0.77, 1.05), P=0.19 
Hypoglycaemia 1.41 (1.04, 1.91), P=0.03 1.09 (0.93, 1.29), P=0.28 1.41 (1.12, 1.77), P=0.003 
Oedema 1.31 (0.85, 2.02), P=0.23 1.09 (0.87, 1.36), P=0.45 0.87 (0.67, 1.13), P=0.28 
Fracture 1.16 (0.70, 1.92), P=0.58 1.09 (0.88, 1.36), P=0.42 1.00 (0.64, 1.58), P=0.68 
 
TZD 
Gastrointestinal 1.21 (0.94, 1.55), P=0.13 1.05 (0.93, 1.18), P=0.44 1.04 (0.87, 1.26), P=0.65 
Hypoglycaemia 1.98 (1.25, 3.15), P=0.004 1.37 (1.11, 1.7), P=0.003 1.44 (0.98, 2.12), P=0.07 
Oedema 1.45 (1.05, 2.01), P=0.03 1.22 (1.07, 1.38), P=0.003 1.01 (0.80, 1.27), P=0.94 
Fracture 1.10 (0.72, 1.68), P=0.65 1.09 (0.93, 1.29), P=0.28 1.05 (0.72, 1.52), P=0.81 
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Figure legends 
 
Figure 1: Approaches to estimating HbA1c (%) response 
Model 1: estimate current HbA1c response using a joint model (red line with black 
dotted 95% confidence intervals). 
Model 2: estimate cumulative HbA1c response using a joint model (grey shaded 
area). 
Model 3: carry forward the most recently observed value of HbA1c response until 
the next measurement (LOCF approach, black step function). 
Model 4: take the observed HbA1c response at a single time point of 6 months (blue 
line). 
 
 
Figure 2: Hazard ratios for the association between HbA1c response and risk 
of a drug-specific side-effect (Models 1-3). Hazard ratios (95% confidence 
intervals) represent the increase in risk of a side-effect for a 1% greater absolute 
HbA1c response. A hazard ratio greater than 1 indicates an increased risk of a side-
effect with greater HbA1c response. 
 
